1040 / 1851
About
50%
of all patients with
NSCLC
present with
metastatic
disease at the time of
diagnosis
Platinum-based doublet
chemotherapy can improve
quality of life and extend
survival
,
but the prognosis
of
patients with metastatic NSCLC remains
extremely poor
,
with MST from 8 to 11 months
Moreover, the
predominant pattern of failure
in patients
with
localized NSCLC is distant
metastatic spread
Oligometastatic NSCLC